Flucinar N (fluocinolon) ointment 15 g.


Manufacturer: Poland

Short-term local treatment of acute and severe non-infectious inflammatory skin diseases (dry forms), which are accompanied by persistent itching or hyperkeratosis and respond to treatment with glucocorticosteroids: seborrheic dermatitis, urticaria, atopic dermatitis, contact allergic eczema, erythema multiforme, lupus erythematosus, psoriasis of hair areas of the skin, advanced psoriasis, splashing lichen.



Flucinar N Storage
active substances: fluocinolone, neomycin;

1 g of ointment contains fluocinolone acetonide 0.25 mg, neomycin sulfate 5 mg;

Excipients: propylene glycol, mineral oil, lanolin, white soft paraffin.

Flucinar N Dosage form

Main physical and chemical properties: light yellow, greasy, soft, translucent mass.

Flucinar N Pharmacotherapeutic group
Active corticosteroids in combination with antibiotics. Fluocinolone acetonide and antibiotics. ATX code D07C CO2.

Pharmacological properties


The effect of the drug is due to the combined effect of fluocinolone acetonide and neomycin sulfate.

Fluocinolone acetonide is a highly active synthetic glucocorticosteroid for external application to the skin. When used as an ointment in a concentration of 0.025% has a strong anti-inflammatory, antipruritic, anti-allergic and vasoconstrictive effect. It has lipophilic properties and is easily absorbed through the skin. After applying 2 g of ointment may reduce the production of adrenocorticotropic hormone (ACTH) by the pituitary gland as a result of suppression of the system “adrenal glands – pituitary gland”.


Fluocinolone acetonide easily penetrates the stratum corneum, where it gradually accumulates and is determined even 15 days after application. Not biotransformed in the skin. After absorption, it is systemically biotransformed, mainly in the liver. Excreted in the urine and in smaller quantities in the bile mainly as a compound with glucuronic acid, as well as in small quantities unchanged.

Absorption of fluocinolone acetonide through the skin is enhanced by applying to sensitive skin anatomical folds of the body and face, as well as on skin with damaged epidermis or inflammation. The use of an occlusive dressing causes an increase in skin temperature and humidity, which also leads to increased absorption of fluocinolone acetonide. In addition, absorption is enhanced by frequent use of the drug and on large areas of skin. Absorption through the skin is higher in adolescents than in adults.

Allergy to corticosteroids, hypersensitivity to aminoglucoside antibiotics or to other components of the drug. Bacterial, fungal and viral dermatitis, chickenpox, pyoderma, herpes, actinomycosis, blastomycosis, sporotrichosis, numerous psoriatic plaques, cutaneous manifestations of syphilis, tuberculosis of the skin, erosive-ulcerative lesions of the gastrointestinal tract, gastrointestinal tract, gastrointestinal tract. , hemangioma, xanthoma, sarcoma, skin tumors, skin cancer, pink and vulgar acne, perianal and genital itching, perioral dermatitis, diaper dermatitis, thrombophlebitis and trophic ulcers on the background of varicose veins. Do not use after vaccination. The drug should not be used on large areas of skin, especially on wounds that do not heal for a long time, such as deep burns. The drug should not be used in ophthalmology.